Acerus Pharma Cash Flow - Quarterly (OTCMKTS:TRLPF)

Add to My Stocks
$0.21 $0 (0%) TRLPF stock closing price Sep 21, 2018 (Closing)

For analyzing any company like Acerus Pharma from an investment perspective, its important to check the cash flow statement. While its important to look at the Acerus Pharma debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as Acerus Pharma revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. This statement can tell if a company is running out of money while still being profitable and is useful in Acerus Pharma stock analysis. Acerus Pharma had a negative net income cash flow of $-8.71M till this quarter of 2017 Q4. This report is very useful in measuring the short term viability of a company. Acerus Pharma has a negative cash and cash equivalents change of $-2.04M.

View and download details of Acerus Pharma cash flows for latest & last 40 quarters
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
-8.71M-6.34M-4.01M-2.07M11.11M11.43M12.38M5.91M
Depreciation Depletion Amortization Cash-Flow1.99M1.53M1M-2.16M1.65M1.11M-
Net Increase (Decrease) in Assets Liabilities5.68M3.19M3.72M-0.37M5.5M3.6M3.14M-
Cash From (used in) Discontinued Operations--------
Other Adjustments Net1.13M2.02M-4.29M-15.57M-14.96M-14.99M-6.45M
Net Cash from (used by) Operating Activities
--1.64M2.35M3.21M1.72M1.64M-
Increase (Decrease) in Prop Plant And Equipment-----0.07M-0.01M-0.01M-
Acquisition Disposition of Subsidiaires--------
Increase (Decrease) in Investments--------
Other Cash Inflow (Outflow) from Investment Activities--------
Net Cash from (used by) Investment Activities
-----0.07M-0.01M-0.01M-
Issuance (Purchase) of Equity Shares----2M2M2M-
Issuance (Repayment) of Debt Securities-1.74M-3.39M-3.62M-3.39M-5.78M-4.71M-4.33M-0.57M
Increase (Decrease) in Bank & Other Borrowings--------
Payment of Dividends & Other Cash Distributions--------
Other Cash from (used by) Financing Activities-0.68M-0.34M-0.42M-0.34M-0.68M-0.52M-0.45M-0.25M
Net Cash from (used by) Financing Activities
-2.43M-3.73M-4.04M-3.73M-4.47M-3.23M-2.79M-0.82M
Effect of Exchange Rate Changes on Cash--------
Net Change in Cash & Cash Equivalents
-2.04M-3.05M-2.29M-1.32M-1.13M-1.2M-0.79M-0.13M
Cash & Equivalents at Beginning of Year31.01M18.11M9.21M14.52M----
Cash & Equivalents at Year End3.15M2.14M2.9M3.87M5.19M5.12M5.53M6.19M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Click here to view our Antares Pharma financial analysis

Acerus Pharma stock price history provides insight into historical stock price fluctuations, and Acerus Pharma stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Acerus Pharma had a Net Change in Cash and Cash Equivalents of $-2.04M in the latest quarter 2017 Q4. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Acerus Pharma stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Acerus Pharma decreased its cash from operating activities to $- till 2017 Q4. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: Acerus Pharma used $- cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash flow from financing activities shows the flow of cash between Acerus Pharma and its owners and creditors and was $-2.43M till 2017 Q4. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Acerus Pharma Cash Flow

FCF margin
0